2.260USD-2.16%Mkt Cap: 95.46M $P/E: —2d ago
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobr…
Industry Peers
Medical DevicesKey Statistics
Company
Market Cap95.46M $
Enterprise Value99.15M $
Revenue (TTM)87.44M $
Gross Profit67.14M $
Net Income (TTM)-54.00M $
Revenue/Share2.098 USD
Last Price2.260 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees296
CountryUS
SectorHealthcare
IndustryMedical Devices
ISINUS7458481014
Valuation
P/E (Trailing)—
P/E (Forward)-2.44
PEG—
EV/EBITDA-2.18
EV/Revenue1.13
P/S1.13
P/B2.52
EPS (TTM)-1.14
EPS (Forward)-0.94
52W Range
1.13064% of range2.890
52W High2.890 USD
52W Low1.130 USD
Profitability
Gross Margin74.19%
Oper. Margin-39.80%
EBITDA Margin-52.02%
Profit Margin-59.67%
ROE-99.79%
ROA-41.77%
Growth
Revenue Growth-4.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.38M $
CapEx (TTM)452.00K $
FCF Margin-13.43%
FCF Yield-12.30%
Net Debt368.00K $
Net Debt/EBITDA-0.01
Balance Sheet
Debt/Equity1.04
Current Ratio4.32
Quick Ratio3.36
Book Value/Sh0.9130 USD
Cash/Share1.300 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.400 USD
Upside (mean)+50.4%
Target Range2.500 USD – 5.000 USD
$2.500+50.4% to mean$5.000
# Analysts5
Ownership
Shares Out.42.24M
Float37.70M
Insiders4.80%
Institutions62.82%
Short Interest
Short Ratio2.1d
Short % Float2.92%
Short % Out.2.47%
Shares Short1.06M
Short (prev mo.)1.15M
Technical
SMA 501.597 (+41.5%)
SMA 2001.645 (+37.4%)
Beta0.28
S&P 52W Chg18.16%
Avg Vol (30d)671.29K
Avg Vol (10d)587.78K
Technical Indicators
RSI (14)63.8
MACD0.2346
MACD Signal0.2088
MACD Hist.+0.0258
BB Upper2.779 USD
BB Middle1.891 USD
BB Lower1.002 USD
BB Width94.01%
ATR (14)0.1914 USD
Vol Ratio (20d)0.69x